Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ARO-033 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ARO-033 | EXPERIMENTAL | Participants will receive either a single dose of ARO-033 on Day 1 (single-ascending dose \[SAD\]) or 2 doses (multiple-ascending dose \[MAD\]) of ARO-033 administered on Day 1 and Day 29. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive either a single dose of placebo on Day 1 (SAD) or 2 doses (MAD) of placebo administered on Day 1 and Day 29. |
| Name | Type | Description |
|---|---|---|
| ARO-033 | DRUG | ARO-033 will be administered as a subcutaneous (SC) injection per schedule specified in the arm description. |
| Placebo | DRUG | Placebo matching to ARO-033 will be administered as SC injection per schedule specified in the arm description. |
Key Inclusion Criteria: * Adults who are not pregnant, not breastfeeding, and do not plan to become pregnant (or impregnate their partners) during the study and for at least 90 days following the end of the study. * Body mass index (BMI) between 18.0 and 35.0 kilograms (kg)/square meter (m\^2), inc...
ARO-033 is an investigational small molecule being studied for use in healthy participants. It is currently in a first-in-human Phase 1 clinical trial to evaluate its safety and tolerability in adults. The drug is not yet approved and remains in clinical development.
ARO-033 is being developed by Arrowhead Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol ARWR. The company is conducting a first-in-human study of ARO-033 in adult participants.
ARO-033 is in Phase 1 clinical development. It is currently being evaluated in a first-in-human study that is recruiting participants. The drug is investigational and has not been approved by regulatory authorities.
ARO-033 is being studied in a Phase 1 clinical trial with the identifier NCT07662096. This first-in-human study is recruiting 42 healthy adult participants in New Zealand. The trial is randomized, double-blind, and placebo-controlled.
ARO-033 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The ongoing trial is designed to assess the safety and tolerability of ARO-033 in healthy participants, and regulatory approval has not been granted.